Australia markets open in 7 hours 44 minutes

Evoke Pharma, Inc. (EVOK)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.4729+0.0209 (+4.62%)
As of 11:40AM EDT. Market open.

Evoke Pharma, Inc.

420 Stevens Avenue
Suite 230
Solana Beach, CA 92075
United States
858 345 1494
https://www.evokepharma.com

Sector(s)Healthcare
IndustryDrug Manufacturers - Specialty & Generic
Full-time employees4

Key executives

NameTitlePayExercisedYear born
Mr. Matthew J. D'Onofrio MBACo-Founder, CEO & Director779.37kN/A1970
Dr. Marilyn R. Carlson D.M.D., M.D., RAC.Chief Medical Officer681.24kN/A1948
Mr. Christopher QuesenberryChief Commercial Officer - Gimoti (TM)N/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Corporate governance

Evoke Pharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.